CGTX - NASDAQ
Cognition Therapeutics, Inc.
$1.42
+14%Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, a sigma-2 receptor antagonist, which is in Phase II clinical trial for the treatment of mild-to-moderate Alzheimer's disease, as well as has completed Phase I clinical trial to treat early-stage Alzheimer's disease; in Phase II clinical trial for the treatment of dementia with Lewy bodies (DLB); and in preclinical trial to treat dry age-related macular degeneration (AMD). The company is also developing CT2168 for the treatment of synucleinopathies, which include DLB and Parkinson's disease; and CT2074 to treat dry AMD. Cognition Therapeutics, Inc. was incorporated in 2007 and is headquartered in Purchase, New York.
At a Glance
Live SnapshotNo Revenue Data
CGTX has not reported any revenue values in the available annual periods.
Cognition Therapeutics, Inc. Profit Bridge
Profitability Analysis
Cognition Therapeutics, Inc. Income Statement
CGTX • NASDAQ
| Cognition Therapeutics, Inc. Income Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|---|---|
REVENUE | |||||||
GROSS PROFIT | |||||||
(228K) | (0.0) | (0.0) | (235K) | (0.0) | (98K) | (81K) | |
-228K | 0.0 | 0.0 | -235K | 0.0 | -98K | -81K | |
OPERATING INCOME | |||||||
(47.8M) | (54M) | (50.7M) | (43.3M) | (28.6M) | (17.3M) | (4.7M) | |
(10.6M) | (12.3M) | (13.5M) | (13.2M) | (10M) | (4.5M) | (3.5M) | |
(37.2M) | (41.7M) | (37.2M) | (30.3M) | (18.6M) | (12.9M) | (14.4M) | |
-47.8M | -54M | -50.7M | -43.6M | -28.6M | -17.4M | -17.8M | |
PRE-TAX INCOME | |||||||
(13K) | (25K) | (0.0) | (28K) | (893K) | (1.8M) | (1M) | |
-13K | -25K | 27K | 22.2M | 16.6M | 9.1M | 12.1M | |
(0.0) | (0.0) | (0.0) | -235K | (0.0) | -98K | -13.2M | |
24.3M | 20M | 24.9M | 22.2M | 16.9M | 9.6M | 0.0 | |
-23.5M | -34M | -25.8M | -21.4M | -11.7M | -7.8M | -4.8M | |
NET INCOME | |||||||
(0.0) | (0.0) | (0.0) | -22.2M | (0.0) | (0.0) | (0.0) | |
-23.5M | -34M | -25.8M | 757K | -11.7M | -10.1M | -7M |
SEC Filings
CGTX - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | May 21, 2026 | May 21, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 08, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 07, 2026 | May 07, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 27, 2026 | June 17, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 26, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | March 26, 2026 | March 26, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 02, 2026 | March 02, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 27, 2026 | January 27, 2026 | 2026 | |
8-K 8-K 2025 N/A | December 18, 2025 | December 16, 2025 | 2025 | |
S-3 S-3 N/A | December 18, 2025 | December 18, 2025 |
Related Guides
Continue your CGTX research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.